From Wikipedia, the free encyclopedia
PRC200-SS
(1S ,2S )-3-(Methylamino)-2-naphthalen-2-yl-1-phenylpropan-1-ol
CAS Number PubChem CID ChemSpider ECHA InfoCard 100.207.294 Formula C 20 H 21 N O Molar mass 291.394 g·mol−1 3D model (JSmol )
O[C@H](c1ccccc1)[C@H](CNC)c2cc3ccccc3cc2
InChI=1S/C20H21NO/c1-21-14-19(20(22)16-8-3-2-4-9-16)18-12-11-15-7-5-6-10-17(15)13-18/h2-13,19-22H,14H2,1H3/t19-,20-/m1/s1
N Key:RSZGIFQDUIROGN-WOJBJXKFSA-N
N
N Y (what is this?)
PRC200-SS is an experimental drug of the triple reuptake inhibitor class that was investigated by the Mayo Clinic .[1] [2]
Preclinical toxicology studies of PRC200-SS in cynomolgus monkeys showed dose proportional kidney toxicity,[3] precluding any further drug development .
References [ ]
^ Liang Y, Shaw AM, Boules M, Briody S, Robinson J, Oliveros A, et al. (November 2008). "Antidepressant-like pharmacological profile of a novel triple reuptake inhibitor, (1S,2S)-3-(methylamino)-2-(naphthalen-2-yl)-1-phenylpropan-1-ol (PRC200-SS)". The Journal of Pharmacology and Experimental Therapeutics . 327 (2): 573–83. doi :10.1124/jpet.108.143610 . PMID 18689611 . S2CID 12635418 .
^ "Triple Reuptake Inhibitors for the Treatment of Depression" . Mayo Clinic Ventures.
^ Guha M, Heier A, Price S, Bielenstein M, Caccese RG, Heathcote DI, et al. (April 2011). "Assessment of biomarkers of drug-induced kidney injury in cynomolgus monkeys treated with a triple reuptake inhibitor" . Toxicological Sciences . 120 (2): 269–83. doi :10.1093/toxsci/kfr013 . PMID 21258088 .
Antidepressants (N06A )
SSRIs
Citalopram
Escitalopram
Fluoxetine #
Fluvoxamine
Indalpine ‡
Paroxetine
Sertraline
Zimelidine ‡
SNRIs NRIs NDRIs
Amineptine ‡
Bupropion
Nomifensine ‡
NaSSAs SARIs SMS Others
Monoamine oxidase inhibitors
Non-selective MAOA -selectiveMAOB -selective
Miscellaneous
Ademetionine (SAMe )
Hypericum perforatum (St. John's Wort)
Oxitriptan (5-HTP )
Rubidium chloride (RbCl)
Tryptophan
# WHO-EM
‡ Withdrawn from market
Clinical trials :
† Phase III
§ Never to phase III
Monoamine reuptake inhibitors
DAT (DRIs )
NET (NRIs )
Others: Antihistamines (e.g., brompheniramine , chlorphenamine , pheniramine , tripelennamine )
Antipsychotics (e.g., loxapine , ziprasidone )
Arylcyclohexylamines (e.g., ketamine , phencyclidine )
Dopexamine
Ephenidine
Ginkgo biloba
Indeloxazine
Nefazodone
Opioids (e.g., desmetramadol , methadone , pethidine (meperidine) , tapentadol , tramadol , levorphanol )
SERT (SRIs )
Others:
Amoxapine
Antihistamines (e.g., brompheniramine , chlorphenamine , dimenhydrinate , diphenhydramine , mepyramine (pyrilamine) , pheniramine , tripelennamine )
Antipsychotics (e.g., loxapine , ziprasidone )
Arylcyclohexylamines (e.g., 3-MeO-PCP , esketamine , ketamine , methoxetamine , phencyclidine )
Cyclobenzaprine
Delucemine
Dextromethorphan
Dextrorphan
Efavirenz
Hypidone
Medifoxamine
Mesembrine
Mifepristone
MIN-117 (WF-516)
N-Me-5-HT
Opioids (e.g., dextropropoxyphene , methadone , pethidine (meperidine) , levorphanol , tapentadol , tramadol )
Roxindole
VMATs Others See also: Receptor/signaling modulators • Monoamine releasing agents • Adrenergics • Dopaminergics • Serotonergics • Monoamine metabolism modulators • Monoamine neurotoxins
Categories :
Serotonin–norepinephrine–dopamine reuptake inhibitors Naphthalenes Amines Secondary alcohols Abandoned drugs Hidden categories:
ECHA InfoCard ID from Wikidata Articles with changed InChI identifier Articles without EBI source Chemical pages without DrugBank identifier Articles without KEGG source Articles without UNII source Drugs missing an ATC code Drugs with no legal status Drugboxes which contain changes to verified fields Drugboxes which contain changes to watched fields